Medtronic's personalized pacemaker wins FDA approval

FDA regulators approve Medtronic's new Viva CRT-P adaptive cardiac pacemaker for treatment of heart failure or atrioventricular block. Medtronic (NYSE:MDT) won FDA approval for its Viva CRT-P cardiac resynchronization therapy-pacemaker, which features proprietary software to adjust its pacing parameters to a patient's heart rhythms minute-by-minute. MedtronicNews Well, Regulatory/Clearance, Cardiac Rhythm Management, Food & Drug Administration (FDA), Minnesota, Pre-Market Approval (PMA)read more
Source: Mass Device - Category: Medical Equipment Authors: Source Type: news